The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats
Vukojevic J, Vrdoljak B, Malekinusic D, Siroglavic M, Milavic M, Kolenc D, Boban Blagaic A, Batelja L, +3 more
Brain and Behavior (2020)
The Sikiric Zagreb group's bilateral-carotid-clamp stroke model in Wistar rats: 10 µg/kg BPC 157 applied as a topical 1 mL bath 30 seconds after a 20-minute reperfusion start prevented hippocampal red-neuron death, restored Morris water maze / beam-walk / lateral-push performance, and shifted the NO-synthase gene-expression panel toward the cytoprotective constitutive isoforms (Nos3, Nos1 up; Nos2 down) — the corpus's load-bearing post-2018 mechanistic candidate for BPC-157 in stroke.
This 2020 paper in Brain and Behavior is the Sikiric Zagreb group's most-cited post-2018 primary-research entry on BPC-157 in a clinically translatable injury model. The paper applies the bilateral-common-carotid-artery clamping rat model — a standard global-forebrain-ischemia paradigm that produces selective delayed hippocampal CA1 neuronal death and reliably reproduces stroke-like cognitive and motor deficits — and asks whether BPC-157 given during the reperfusion phase can prevent the ischemic damage. The authors' answer is yes, and the paper supplies both a functional-recovery readout (Morris water maze, inclined beam-walk, lateral push test, all returning to pre-surgery baseline) and a histological readout (significantly fewer "red neurons" and more healthy neurons in hippocampal tissue) to support it. The mechanistic substrate is documented at the transcript level: a hippocampal mRNA panel run at 1 hour and 24 hours after reperfusion shows strong upregulation of cytoprotective NO-synthase isoforms (Nos3, Nos1), growth and survival signaling (Egr1, Akt1, Kras, Src, Foxo, Srf, Vegfr2), and downregulation of the inducible inflammatory isoform Nos2 along with the master inflammatory transcription factor Nfkb. Mapk1 was not activated.
The paper is the corpus's load-bearing post-2018 Sikiric-group mechanism paper. It moves the BPC-157 story past the 2018 Current Pharmaceutical Design review's vascular-recruitment framing and into a specific, transcript-resolved, behavior-validated stroke model — the closest the Zagreb group has come to a stroke-translational mechanism paper in the years between the 2018 review and the 2022 World J Gastroenterol editorial summary on major vessel occlusion. It also operationalizes the NO-system-modulation hypothesis the 2018 review proposed: in this paper, the constitutive NO-synthase isoforms (Nos3 endothelial, Nos1 neuronal) are upregulated while the inducible inflammatory isoform (Nos2) is downregulated, providing a mechanistic substrate for the "cytoprotective NO" framing the program has used for years.
This is a single-laboratory rat-model study from the inventor group; the Vukojevic / Sikiric Zagreb team has published the bulk of the world's BPC-157 literature for three decades. The route of administration in this paper is topical — a 1 mL bath applied directly to the surgical area at the trigonum caroticum at 30 seconds post-reperfusion. This is not a route of administration that translates directly to human use (where systemic intravenous, subcutaneous, or oral dosing would be required); the topical-bath route maximizes local peptide concentration at the carotid surgical site without forcing translation of pharmacokinetic exposure to the equivalent of a clinical dose. A systemic-route version of the same experiment would be the natural next-step replication, and the Vukojevic / Sikiric group does have systemic-route BPC-157 stroke papers elsewhere in the program literature, but the present paper's headline result is for the topical-bath protocol.
The model itself — 20 minutes of bilateral common carotid clamping in Wistar rats — produces a selective hippocampal injury that is highly reproducible but does not capture all the pathophysiology of human ischemic stroke (large-vessel embolic occlusion with focal cortical infarct, longer ischemic windows, comorbid cardiovascular disease, late thrombolytic therapy). The paper's claim is for the bilateral-common-carotid-clamp model, not for the full stroke clinical syndrome.
The mRNA panel is a transcript-level readout. Protein-level confirmation of the proposed NOS isoform shift (Nos3 / Nos1 up at protein; Nos2 down at protein) is not present in this paper. The downstream functional NO assays (cGMP measurement, endothelial-dependent vasorelaxation) that would close the loop on the "cytoprotective NO" mechanism are not present in this paper. The transcript-level signal is consistent with the proposed mechanism but does not by itself establish it.
The paper has not been independently replicated outside the Zagreb group's network, and no human stroke trial of BPC-157 has been published. Read the result as a robust rat-model mechanism paper with a strongly suggestive transcript-level mechanism — not as evidence that BPC-157 prevents stroke damage in humans, and not as evidence that topical-bath protocols translate to systemic dosing routes.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.